

STEP THERAPY POLICY

- POLICY:** Parkinson's Disease – Monoamine Oxidase Type B Inhibitors Step Therapy Policy
- Azilect® (rasagiline tablets – Teva, generic)
 - Selegiline capsules and tablets (generic only)
 - Xadago® (safinamide mesylate tablets – US Worldmeds)

REVIEW DATE: 01/20/2021

OVERVIEW

Azilect, oral selegiline products, and Xadago are monoamine oxidase type B (MAO-B) inhibitors and have similar indications for the **treatment of Parkinson's disease**.¹⁻³ Azilect is indicated for the treatment of Parkinson's disease. Selegiline tablets and capsules are indicated as adjuncts in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. Xadago is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes.

The International Parkinson and Movement Disorder Society published an evidence-based review for treatment for motor symptoms of Parkinson's disease (2018).⁴ All MAO-B inhibitors are addressed. The review categorically divides treatment recommendations by Parkinson's disease characteristics. Azilect and selegiline are treatments considered to be efficacious and clinically useful for symptomatic monotherapy. For the treatment of motor fluctuations, Azilect and Xadago are noted to be efficacious and clinically useful while selegiline is considered efficacious and possibly useful.

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. Zelapar® (selegiline orally disintegrating tablets) does not require Step Therapy for coverage. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: A patient with a history of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic selegiline tablets and capsules, generic rasagiline tablets

Step 2: Azilect, Xadago

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. No other exceptions are recommended.

REFERENCES

1. Azilect[®] tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; June 2020.
2. Selegiline capsules and tablets [prescribing information]. Weston, FL: Apotex Corp.; November 2018.
3. Xadago[®] tablets [prescribing information]. Louisville, KY: US WorldMeds, LLC; December 2020.
4. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Mov Disord*. 2018;33(8):1248-1266.